PE20142439A1 - Formulacion en capsulas solubilizadas de [(1s)-1-{[(2s,4r)-4-(7-cloro-4metoxiisoquinolin-1-iloxi)-2-({(1r,2s)-1-[(ciclopropilsulfonil)carbamoil]-2-etenilciclopropil}carbamoil)pirrolidin-1-il]carbonil}-2,2-dimetilpropil]carbamato de 1,1-dietiletilo - Google Patents
Formulacion en capsulas solubilizadas de [(1s)-1-{[(2s,4r)-4-(7-cloro-4metoxiisoquinolin-1-iloxi)-2-({(1r,2s)-1-[(ciclopropilsulfonil)carbamoil]-2-etenilciclopropil}carbamoil)pirrolidin-1-il]carbonil}-2,2-dimetilpropil]carbamato de 1,1-dietiletiloInfo
- Publication number
- PE20142439A1 PE20142439A1 PE2014001988A PE2014001988A PE20142439A1 PE 20142439 A1 PE20142439 A1 PE 20142439A1 PE 2014001988 A PE2014001988 A PE 2014001988A PE 2014001988 A PE2014001988 A PE 2014001988A PE 20142439 A1 PE20142439 A1 PE 20142439A1
- Authority
- PE
- Peru
- Prior art keywords
- carbamoil
- dimethylpropyl
- pyrrolidin
- carbamate
- carbonyl
- Prior art date
Links
- UGFAIRIUMAVXCW-UHFFFAOYSA-N Carbon monoxide Chemical compound [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 title 1
- XIPUIGPNIDKXJU-UHFFFAOYSA-N [CH]1CC1 Chemical compound [CH]1CC1 XIPUIGPNIDKXJU-UHFFFAOYSA-N 0.000 title 1
- 239000002775 capsule Substances 0.000 title 1
- SLWGJZPKHAXZQL-UHFFFAOYSA-N emylcamate Chemical compound CCC(C)(CC)OC(N)=O SLWGJZPKHAXZQL-UHFFFAOYSA-N 0.000 title 1
- 238000009472 formulation Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- -1 7-chloro-4-methoxyisoquinolin-1-yloxy Chemical group 0.000 abstract 2
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 abstract 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 abstract 1
- 241000711549 Hepacivirus C Species 0.000 abstract 1
- XRWSZZJLZRKHHD-WVWIJVSJSA-N asunaprevir Chemical compound O=C([C@@H]1C[C@H](CN1C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)OC1=NC=C(C2=CC=C(Cl)C=C21)OC)N[C@]1(C(=O)NS(=O)(=O)C2CC2)C[C@H]1C=C XRWSZZJLZRKHHD-WVWIJVSJSA-N 0.000 abstract 1
- 229960002118 asunaprevir Drugs 0.000 abstract 1
- 239000007963 capsule composition Substances 0.000 abstract 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261643454P | 2012-05-07 | 2012-05-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20142439A1 true PE20142439A1 (es) | 2015-01-28 |
Family
ID=48428670
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2014001988A PE20142439A1 (es) | 2012-05-07 | 2013-04-30 | Formulacion en capsulas solubilizadas de [(1s)-1-{[(2s,4r)-4-(7-cloro-4metoxiisoquinolin-1-iloxi)-2-({(1r,2s)-1-[(ciclopropilsulfonil)carbamoil]-2-etenilciclopropil}carbamoil)pirrolidin-1-il]carbonil}-2,2-dimetilpropil]carbamato de 1,1-dietiletilo |
Country Status (33)
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2673870T3 (es) * | 2012-05-07 | 2018-06-26 | Bristol-Myers Squibb Holdings Ireland | Formulación de dosificación oral sólida de [(1S)-1-{[(2S,4R)-4-(7-cloro-4-metoxiisoquinolin-1-iloxi)-2-({(1R,2S)-1-[(ciclopropilsulfonil) carbamoil]-2-etenilciclopropil} carbamoil) pirrolidin-1-il] carbonil}-2,2-dimetil-propil] carbamato de 1,1-dimetiletilo |
| JP6154474B2 (ja) | 2012-10-19 | 2017-06-28 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | Ｃ型肝炎ウイルス阻害剤 |
| US9643999B2 (en) | 2012-11-02 | 2017-05-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| WO2014071007A1 (en) | 2012-11-02 | 2014-05-08 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
| EP2914613B1 (en) | 2012-11-02 | 2017-11-22 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
| EP2914614B1 (en) | 2012-11-05 | 2017-08-16 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
| EP2964664B1 (en) | 2013-03-07 | 2017-01-11 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
| WO2019130341A1 (en) * | 2017-12-26 | 2019-07-04 | Hetero Labs Limited | Capsule compositions comprising lopinavir and ritonavir |
| EA202092131A1 (ru) | 2018-03-14 | 2020-11-27 | Кэнди Терапьютикс Лимитед | Новый фармацевтический препарат, содержащий двойные антагонисты рецептора nk-1/nk-3 |
| US12533358B1 (en) | 2025-05-14 | 2026-01-27 | Bayer Consumer Care Ag | Methods of treatment with elinzanetant |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA9710071B (en) * | 1996-11-21 | 1998-05-25 | Abbott Lab | Pharmaceutical composition. |
| ES2298286T3 (es) * | 2000-10-31 | 2008-05-16 | Boehringer Ingelheim Pharmaceuticals Inc. | Formulaciones de dosis orales auto-emulsionantes de inhibidores de proteasa de piranona. |
| US6828301B2 (en) * | 2002-02-07 | 2004-12-07 | Boehringer Ingelheim International Gmbh | Pharmaceutical compositions for hepatitis C viral protease inhibitors |
| MY140680A (en) | 2002-05-20 | 2010-01-15 | Bristol Myers Squibb Co | Hepatitis c virus inhibitors |
| WO2010042834A1 (en) * | 2008-10-09 | 2010-04-15 | Anadys Pharmaceuticals, Inc. | A method of inhibiting hepatitis c virus by combination of a 5,6-dihydro-1h-pyridin-2-one and one or more additional antiviral compounds |
| US8252821B2 (en) * | 2009-04-14 | 2012-08-28 | Bristol-Myers Squibb Company | Bioavailable capsule compositions of amorphous alpha-(N-sulfonamido)acetamide compound |
-
2013
- 2013-04-29 US US13/872,652 patent/US20130302414A1/en not_active Abandoned
- 2013-04-30 PE PE2014001988A patent/PE20142439A1/es not_active Application Discontinuation
- 2013-04-30 NZ NZ630248A patent/NZ630248A/en not_active IP Right Cessation
- 2013-04-30 HR HRP20181583TT patent/HRP20181583T1/hr unknown
- 2013-04-30 EA EA201492039A patent/EA028749B1/ru not_active IP Right Cessation
- 2013-04-30 KR KR20147033971A patent/KR20150004921A/ko not_active Ceased
- 2013-04-30 BR BR112014027676A patent/BR112014027676A2/pt not_active IP Right Cessation
- 2013-04-30 CA CA2872765A patent/CA2872765A1/en not_active Abandoned
- 2013-04-30 JP JP2015511510A patent/JP6276756B2/ja not_active Expired - Fee Related
- 2013-04-30 WO PCT/US2013/038770 patent/WO2013169520A1/en not_active Ceased
- 2013-04-30 ES ES13722217.0T patent/ES2688817T3/es active Active
- 2013-04-30 DK DK13722217.0T patent/DK2846780T3/en active
- 2013-04-30 MY MYPI2014703294A patent/MY171378A/en unknown
- 2013-04-30 MX MX2014013220A patent/MX358545B/es active IP Right Grant
- 2013-04-30 SG SG11201406964QA patent/SG11201406964QA/en unknown
- 2013-04-30 RS RS20181141A patent/RS57881B1/sr unknown
- 2013-04-30 CN CN201380023724.1A patent/CN104363899A/zh active Pending
- 2013-04-30 SI SI201331126T patent/SI2846780T1/sl unknown
- 2013-04-30 PL PL13722217T patent/PL2846780T3/pl unknown
- 2013-04-30 AU AU2013260005A patent/AU2013260005B2/en not_active Ceased
- 2013-04-30 LT LTEP13722217.0T patent/LT2846780T/lt unknown
- 2013-04-30 PT PT13722217T patent/PT2846780T/pt unknown
- 2013-04-30 EP EP13722217.0A patent/EP2846780B1/en active Active
- 2013-04-30 SM SM20180506T patent/SMT201800506T1/it unknown
- 2013-05-06 AR ARP130101544A patent/AR090954A1/es unknown
- 2013-05-06 UY UY0001034785A patent/UY34785A/es unknown
- 2013-05-06 TW TW102116102A patent/TWI577392B/zh not_active IP Right Cessation
-
2014
- 2014-10-27 PH PH12014502405A patent/PH12014502405A1/en unknown
- 2014-11-03 IL IL235466A patent/IL235466B/en active IP Right Grant
- 2014-11-06 CL CL2014003012A patent/CL2014003012A1/es unknown
- 2014-12-02 CO CO14265249A patent/CO7141457A2/es unknown
- 2014-12-05 ZA ZA2014/08967A patent/ZA201408967B/en unknown
-
2018
- 2018-10-15 CY CY181101051T patent/CY1120756T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201791019A1 (ru) | Полициклические карбамоилпиридоновые соединения и их фармацевтическое применение | |
| HK1207829A1 (zh) | 疫苗 | |
| EA201791872A1 (ru) | Полициклические карбамоилпиридоновые соединения и их фармацевтическое применение | |
| PE20150204A1 (es) | Inhibidores de virus de hepatitis c | |
| EA201591027A1 (ru) | Полициклические карбамоилпиридоновые соединения и их фармацевтическое применение | |
| EA201492039A1 (ru) | Солюбилизированный капсулированный препарат 1,1-диметилэтил [(1s)-1-{[(2s,4r)-4-(7-хлор-4-метоксиизохинолин-1-илокси)-2-({(1r,2s)-1-[(циклопропилсульфонил)карбамоил]-2-этенилциклопропил}карбамоил)пирролидин-1-ил]карбонил}-2,2-диметилпропил]карбамата | |
| AR102463A1 (es) | Inhibidor de cinasa aurora a | |
| PE20140038A1 (es) | Compuestos antivirales | |
| CL2012001449A1 (es) | Uso de combinaciones del compuesto n-[(ciclopentiloxi)carbonil]-3-metil-l-valiol-(4r)-4-({8-bromo-2-[2-(isobutirilamino)-1,3-tiazol-4-il]-7-metoxi-4-quinolinil}oxi)-n-[(1r,2s)-1-carboxi-2-vinilciclopropil]-l-prolinamida; y envase que comprende las formas de dosificacion. | |
| EA201592256A1 (ru) | Производные имидазопирролидинона и их применение при лечении заболеваний | |
| EA201592250A1 (ru) | Пиразолопирролидиновые производные и их применение в лечение заболеваний | |
| UA115807C2 (uk) | Композиція (варіанти) ценікривіроку і спосіб її одержання та застосування (варіанти) | |
| EA201792235A1 (ru) | Инъецируемые препараты замедленного высвобождения, содержащие изоксазолиновое действующее вещество, способы и применение | |
| EA201690687A1 (ru) | Ингибиторы репликации вируса иммунодефицита | |
| PH12015501156A1 (en) | Pharmaceutical compositions | |
| IN2014MN02236A (enExample) | ||
| EA201500710A1 (ru) | Фармацевтическая композиция для лечения вич-инфекций | |
| EA201691490A1 (ru) | Фармацевтическая композиция, содержащая бринзоламид | |
| EA201300132A1 (ru) | Фармацевтическая композиция и методы лечения и профилактики заболеваний, вызванных вич или ассоциированных с вич | |
| HRP20180333T1 (hr) | Pripravci koji sadrže vortioksetin i donepezil | |
| CA3010788A1 (en) | Methods of administering vasopressors | |
| EA201590460A1 (ru) | Способ и средство для лечения и профилактики заболеваний, вызываемых (+)рнк-содержащими вирусами | |
| EA201590474A1 (ru) | ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ НА ОСНОВЕ КОМПОЗИТНЫХ КАПСУЛ, ВКЛЮЧАЮЩИХ ИРБЕСАРТАН И ИНГИБИТОР ГМГ-КоА РЕДУКТАЗЫ | |
| WO2015086738A3 (en) | Hiv vaccine | |
| EA201990550A1 (ru) | Офтальмологический препарат, включающий азоловое соединение |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |